Hebei Changshan Biochem Pharma (300255.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE1000016C2

Price
19.42 CNY
Market cap
17.85 bn CNY
P/E (2025)
–
P/S (2025)
20.39
Dividend yield
0.00 %
Net margin
-40.90 %
Return on equity (ROE)
-29.72 %
Return on assets (ROA)
-8.23 %

Hebei Changshan Biochem Pharma financials

Fiscal year20242025
Revenue1.03 bn CNY875.13 m CNY
Gross profit93.46 m CNY132.41 m CNY
Operating income-254.04 m CNY-92.80 m CNY
EBIT-178.78 m CNY-258.98 m CNY
Net income-249.48 m CNY-357.90 m CNY
Diluted EPS – continuing operations-0.27 CNY-0.39 CNY

Full history since 2008, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Hebei Changshan Biochem Pharma

Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide. The company is also involved in technology development; consulting; transfer services; investment and management of medical service projects; wholesale and retail of pharmaceuticals; and diagnosis services. It exports its products to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries. The company was founded in 1992 and is based in Shijiazhuang, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 26.10.2026. Details in the risk notice.